Wire · operational-macro
Edesa Biotech gets FDA clearance for up-to-80-person trial
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 15 October 2026 · Fusion42 review
Edesa Biotech received FDA clearance for its IND application to conduct a Phase 2 clinical trial of EB06, a monoclonal antibody for moderate-to-severe vitiligo, expanding recruitment to the US with topline data expected in Q4 2027.
This Wire brief sits within Fusion42's coverage of Biotech, and 6 sources have reported it between 15 Oct 2026 and 16 Oct 2026.
◆ ◆ The Wire takeaway
You now have access to the US vitiligo trial market as FDA clearance opens patient recruitment for EB06. Start planning your regulatory and US clinical partnerships to move fast on similar autoimmune or dermatological treatments.
◆ Coverage
6 sources · first reported 15 Oct 2026 · latest 16 Oct 2026
◆ Related on Wire
◆ Topics